AU2015271692B2 - Benzimidazole analogues and related methods - Google Patents

Benzimidazole analogues and related methods Download PDF

Info

Publication number
AU2015271692B2
AU2015271692B2 AU2015271692A AU2015271692A AU2015271692B2 AU 2015271692 B2 AU2015271692 B2 AU 2015271692B2 AU 2015271692 A AU2015271692 A AU 2015271692A AU 2015271692 A AU2015271692 A AU 2015271692A AU 2015271692 B2 AU2015271692 B2 AU 2015271692B2
Authority
AU
Australia
Prior art keywords
phenyl
imidazol
benzo
acetamide
isoxazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015271692A
Other languages
English (en)
Other versions
AU2015271692A1 (en
Inventor
Francesca CARLOMAGNO
Brendan FRETT
Hong-Yu Li
Massimo SANTORO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universita Federico Ii
Arizona's Public Universities
Original Assignee
Federico Ii, University of
University of Arizona
Arizona's Public Universities
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Federico Ii, University of, University of Arizona, Arizona's Public Universities filed Critical Federico Ii, University of
Publication of AU2015271692A1 publication Critical patent/AU2015271692A1/en
Application granted granted Critical
Publication of AU2015271692B2 publication Critical patent/AU2015271692B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10002—Non-specific protein-tyrosine kinase (2.7.10.2), i.e. spleen tyrosine kinase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Catalysts (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2015271692A 2014-06-03 2015-06-03 Benzimidazole analogues and related methods Ceased AU2015271692B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462007321P 2014-06-03 2014-06-03
US62/007,321 2014-06-03
PCT/US2015/033962 WO2015187818A1 (en) 2014-06-03 2015-06-03 Benzimidazole analogues and related methods

Publications (2)

Publication Number Publication Date
AU2015271692A1 AU2015271692A1 (en) 2016-12-22
AU2015271692B2 true AU2015271692B2 (en) 2019-05-23

Family

ID=54767311

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015271692A Ceased AU2015271692B2 (en) 2014-06-03 2015-06-03 Benzimidazole analogues and related methods

Country Status (7)

Country Link
US (1) US9988371B2 (enExample)
EP (1) EP3152194B8 (enExample)
JP (1) JP6612857B2 (enExample)
CN (1) CN107074778B (enExample)
AU (1) AU2015271692B2 (enExample)
ES (1) ES2742192T3 (enExample)
WO (1) WO2015187818A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107176951A (zh) * 2016-03-11 2017-09-19 恩瑞生物医药科技（上海）有限公司 一种脲类化合物、其制备方法及其医药用途
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
EP3740486A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
EP3856186A4 (en) * 2018-09-28 2022-07-06 Arizona Board of Regents on behalf of the University of Arizona SMALL MOLECULAR DYRK1/CLK INHIBITORS AND USES THEREOF
US12365685B2 (en) 2019-02-18 2025-07-22 Shenzhen Targetrx, Inc. Substituted fused aromatic ring derivative, composition and use thereof
ES2995214T3 (en) * 2019-03-06 2025-02-07 C4 Therapeutics Inc Heterocyclic compounds for medical treatment
CN112300106B (zh) * 2020-10-30 2023-03-03 徐州医科大学 一种蛋白激酶抑制剂及制备方法与应用
CN112778294A (zh) * 2021-01-07 2021-05-11 苏州安睿药业有限公司 5-氨基异噁唑衍生物及其在制备多激酶抑制剂中的应用
CN115198256A (zh) * 2022-07-13 2022-10-18 上海天承化学有限公司 一种用于聚酰亚胺薄膜的化学镀铜用还原液及其制备方法和应用
WO2024206989A2 (en) * 2023-03-30 2024-10-03 Bioventures, Llc Flt3 inhibitors and methods of using the same
CN121081464B (zh) * 2025-11-10 2026-02-03 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） 小分子抑制剂pz1在治疗kit突变阳性急性髓系白血病中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120184561A1 (en) * 2005-04-14 2012-07-19 Guido Bold Phenylacetamides suitable as protein kinase inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030225054A1 (en) 2002-06-03 2003-12-04 Jingwu Duan Combined use of tace inhibitors and COX2 inhibitors as anti-inflammatory agents
WO2005048953A2 (en) * 2003-11-13 2005-06-02 Ambit Biosciences Corporation Amide derivatives as kinase modulators
DOP2006000051A (es) 2005-02-24 2006-08-31 Lilly Co Eli Inhibidores de vegf-r2 y métodos
EP2462135A1 (en) * 2009-08-07 2012-06-13 Janssen R&D Ireland Bis-benzimidazole derivatives as hepatitis c virus inhibitors
UA108211C2 (uk) 2009-11-04 2015-04-10 Янссен Рід Айрленд Бензімідазолімідазольні похідні
WO2011150201A2 (en) * 2010-05-27 2011-12-01 Ambit Biosciences Corporation Azolyl amide compounds and methods of use thereof
WO2012088266A2 (en) * 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
US20140315881A1 (en) * 2011-07-29 2014-10-23 Tempero Pharmaceuticals, Inc. Compounds and methods

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120184561A1 (en) * 2005-04-14 2012-07-19 Guido Bold Phenylacetamides suitable as protein kinase inhibitors

Also Published As

Publication number Publication date
EP3152194B1 (en) 2019-05-15
EP3152194B8 (en) 2019-10-09
CN107074778B (zh) 2019-12-13
US9988371B2 (en) 2018-06-05
EP3152194A1 (en) 2017-04-12
EP3152194A4 (en) 2018-01-24
JP2017519818A (ja) 2017-07-20
ES2742192T3 (es) 2020-02-13
AU2015271692A1 (en) 2016-12-22
WO2015187818A1 (en) 2015-12-10
JP6612857B2 (ja) 2019-11-27
US20170101401A1 (en) 2017-04-13
CN107074778A (zh) 2017-08-18

Similar Documents

Publication Publication Date Title
EP3152194B1 (en) Benzimidazole derivatives
TWI855000B (zh) Ｓｔｉｎｇ促效化合物
JP5442906B2 (ja) キナーゼインヒビターおよびこれを用いた癌の治療方法
US10106538B2 (en) Inhibitors of protein kinases
CN118221698A (zh) Kras g12d抑制剂
KR20200100429A (ko) 단백질 키나아제 저해 활성을 갖는 신규한 피리도[3,4-d]피리미딘-8-온 유도체 및 이를 포함하는 암의 예방, 개선 또는 치료용 약학 조성물
CN103958479A (zh) 吡唑并喹啉酮衍生物、其制备和其治疗用途
CN113527335A (zh) 作为egfr抑制剂的大环类化合物及其应用
CN107735399A (zh) 作为蛋白质激酶的调节剂的手性二芳基大环
CN106573906A (zh) 哌啶‑二酮衍生物
WO2001083456A1 (en) Condensed heteroaryl derivatives
WO2013064068A1 (zh) 噻吩并嘧啶和呋喃并嘧啶类衍生物、其制备方法及其在医药上的应用
EA030558B1 (ru) Применение производных пиразолопиридина для лечения рака мочевого пузыря
EA037103B1 (ru) Производные пиридина, обладающие избирательной ингибирующей активностью в отношении ret киназы
JP6512714B2 (ja) 低分子Ｃ−Ｍｙｃ阻害剤
CN108239071B (zh) 酰胺及硫代酰胺类衍生物及其制备方法和应用
CN107531683A (zh) Usp7抑制剂化合物及使用方法
JP2018513214A (ja) 新規なキナーゼ阻害剤の調製と使用
EA018716B1 (ru) Новые 4-(тетразол-5-ил) хиназолиновые производные в качестве противораковых средств
JP2020529465A (ja) キナーゼ阻害剤として有用な置換ピラゾロピリミジン
CN109071462B (zh) 喹唑啉衍生物或其盐和包含其的药物组合物
KR20210156400A (ko) Ｃｄｋ 저해제 화합물 및 이의 의약 용도
CN110407839A (zh) 含杂芳基酰胺结构的三唑并杂环类化合物的制备及应用
HK1242677A1 (en) Benzimidazole analogues and related methods
HK1242677B (en) Benzimidazole analogues and related methods

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired